论文部分内容阅读
目的 :分析 6 4例晚期恶性肿瘤患者化疗前后CD8+ 、CD8+ CD2 8+ 、CD8+ CD2 8- 的变化 ,并探讨其与病情的关系。方法 :采用流式细胞术检测 6 4例晚期恶性肿瘤患者治疗前后T淋巴细胞亚群 ,并与健康体检者作比较。结果 :实验组晚期恶性肿瘤患者化疗前CD4 + 低于对照组 (P <0 0 5 ) ,而化疗前后CD4 + CD8+ 明显低于对照组 (P <0 0 1) ,CD8+ 、CD8+ CD2 8- 明显高于对照组 (P <0 0 1)。治疗后 ,化疗有效者CD4 + 、CD4 + CD8+ 、CD8+ CD2 8+ 升高 (P <0 0 5、P <0 0 1) ,而CD8+ CD2 8- 降低 (P <0 0 5 ) ;化疗无效者CD4 + CD8+ 、CD8+ CD2 8+ 降低 (P <0 0 5、P <0 0 1) ,CD8+ CD2 8- 升高 (P <0 0 1)。结论 :晚期恶性肿瘤患者T淋巴细胞免疫功能低下 ,有效的治疗能提高患者的T淋巴细胞免疫功能 ,临床上检测CD8+ 、CD8+ CD2 8+ 、CD8+ CD2 8- 对恶性肿瘤的治疗和预后有一定的监测作用。
OBJECTIVE: To analyze the changes of CD8 +, CD8 + CD2 +, CD8 + CD8-8 before and after chemotherapy in 64 patients with advanced malignant tumor and to explore their relationship with the disease. Methods: Flow cytometry was used to detect T lymphocyte subsets in 64 patients with advanced malignant tumor before and after treatment, and compared with healthy subjects. Results: The CD4 + levels in patients with advanced malignant tumor before chemotherapy in the experimental group were significantly lower than those in the control group (P <0.05), while the levels of CD4 + CD8 + in the experimental group were significantly lower than those in the control group (P <0.01) Higher than the control group (P <0.01). The levels of CD4 +, CD4 + CD8 + and CD8 + CD28 + in patients with chemotherapy were significantly higher after chemotherapy (P <0.05, P <0.01), while CD8 + CD8 8- was lower (P <0.05) CD4 + CD8 +, CD8 + CD28 + decreased (P <0.05, P <0.01) and CD8 + CD28 increased (P <0.01). Conclusion: T lymphocyte immune function is low in advanced malignant tumor patients. Effective treatment can improve the immune function of T lymphocytes in patients with malignant tumor. The detection of CD8 +, CD8 + CD8 +, CD8 + Monitoring effect.